NCT01371604View on ClinicalTrials.gov

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

October 31, 2014

Conditions
Hepatitis C, Chronic
Interventions
DRUG

IDX184

IDX184 50 mg tablet administered orally

BIOLOGICAL

Peginterferon alfa-2a (Peg-IFN)

Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly

DRUG

Ribavirin (RBV)

Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.

DRUG

Placebo

Matching placebo to IDX184 50 mg tablet administered orally

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01371604 - Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005) | Biotech Hunter | Biotech Hunter